2026년 2월 26일 · Unknown · financial · 출처 Nasdaq
Image source: The Motley Fool.
DATE
Wednesday, Feb. 25, 2026 at 8 a.m. ET
CALL PARTICIPANTS
Chief Executive Officer — Najat KhanChief Financial Officer — Ben TaylorChief Scientific Officer — Dave Hallett
Need a quote from a Motley Fool analyst? Email pr@fool.com
TAKEAWAYS
Partnership and Milestone Revenue -- Over $500 million in cumulative partnership cash inflows, including $134 million to date from Sanofi (composed of $100 million upfront and $34 million in milestones).Operating Expense Reduction -- 35% year-over-year drop in pro forma operating expenses attributed to focused portfolio selection, G&A optimization, and improved platform efficiency.Cash Position -- $754 million in cash at period end, with projected operating expenses (non-GAAP cash basis) under $390 million for the coming year.Cash Runway Guidance -- Runway now expected to extend into early 2028, reflecting both cost discipline and partner payments.Clinical Proof of Concept -- REC-4881 for FAP achieved positive Phase 2 proof of concept; median polyp burden reduction reached 43%, with 75% of patients showing response and durable effects observed off treatment.Drug Discovery Platform Metrics -- Recursion Pharmaceuticals(NASDAQ:RXRX) synthesized an average of 330 compounds per development candidate, 90% fewer than the industry norm of 2,500, and moved candidates to advanced stage in 17 months versus the industry’s typical 40+ months.Sanofi Collaboration -- Five lead packages delivered and accepted, with joint portfolio targeting I&I and oncology indications and potential for each program exceeding $300 million in milestones plus tiered, up-to-double-digit royalties.Data Infrastructure Scale -- Proprietary datasets exceed 50 petabytes of high-quality multimodal data supporting foundational models in phenomics and transcriptomics.Pipeline Diversity -- Five clinical-stage programs (including REC-4881, RBM39, CDK7, ENPP1, MALT1, LSD1) with multiple additional candidates advancing through preclinical and IND-enabling phases.AI-Enabled Clinical Operations -- Enrollment rates improved 1.3x to 1.6x versus prior methods, and study starts accelerated by up to three months, as enabled by the company’s clinical AI platform covering data from 300 million patient lives.Upcoming Milestones -- Phase 1 data updates for RBM39, MALT1, and LSD1, as well as go/no-go IND decisions for PI3K H1047 mutant-selective and ENPP1, are anticipated in the next 12-24 months.Technology Partnerships -- Nvidia(NASDAQ:NVDA) remains a technical partner on supercomputing and model training; Alphabet(NASDAQ:GOOGL) is a partner for cloud compute, with no planned changes to these core relationships despite Nvidia's recent portfolio realignment.
SUMMARY
Recursion Pharmaceuticals(NASDAQ:RXRX) highlighted its transition to an outcomes-based budgeting approach, explicitly tying spending to quantifiable return and ongoing pipeline advancement. Management stated that non-GAAP cash operating expenses for 2026 are projected to remain below $390 million, with extended cash runway guidance to early 2028 integrating projected milestone inflows. The company emphasized that platform efficiency could continue to increase as additional discovery and partnership milestones are realized and more clinical data is generated. Collaboration milestones with Sanofi(NASDAQ:SNY) and progress on AI-driven drug discovery set the stage for substantial late-stage candidate pipeline advances over the next two years.
Company leadership described the business as moving beyond model building to focus on unlocking value through tangible clinical and partnership deliverables.Management stated, "it is also a validation of the platform and a validation that we are learning fast," pointing to cumulative platform improvement as a key pillar of the investment case.Multiple programs aim for first-in-class or best-in-class molecule optimization using proprietary data and rapid in silico design cycles, which the team claimed is shortening the timeline to clinical proof.Clinical pipeline differentiation includes targets selected for high unmet need, proprietary biological insight, or unique optimization for tolerability and oral dosing.
INDUSTRY GLOSSARY
FAP: Familial adenomatous polyposis, a genetic disorder causing large numbers of precancerous colon polyps with high risk for colorectal cancer.Phenomics: Study and model-based analysis of organism-wide phenotypes at large scale, often using high-content data and imaging in drug discovery.IND-Enabling: Preclinical studies and development work required to support the filing of an Investigational New Drug (IND) application for first-in-human clinical trials.PK: Pharmacokinetics, the study of how a drug is absorbed, distributed, metabolized, and excreted by the body.DLT: Dose-Limiting Toxicity, an adverse effect of a drug which prevents an increase in dose or level of that drug.
Full Conference Call Transcript
Najat Khan: Good morning, and thank you so much for joining us. I want to start by briefly framing where Recursion Pharmaceuticals, Inc. is today in its journey and evolution. Over the past decade, Recursion Pharmaceuticals, Inc. has built something truly special: a differentiated platform pioneering the integration of large-scale biological data generation, machine learning, and compute to better understand the complexity of biology. We have also deliberately strengthened the foundation in chemistry and AI through the acquisitions of Excientia, Valens, and Cyclica, creating a truly powerful foundation. Today, we are at an important inflection point. We are harnessing everything that we have built to date to do two things.
Number one, translating insights into evidence—evidence that this platform, the use of AI end to end, can generate medicines that matter—and we are doing this both across our wholly owned portfolio and through our partnerships. With strong momentum across both fronts, I am excited to share some of the updates today. In pa…